Muscle-specific tyrosine kinase antibody positive myasthenia gravis (MuSK+ MG) is an immunological subtype with distinctive pathogenic mechanisms and clinical features. The aim of this study was to analyze the circulating plasma microRNA profile of patients with MuSK+ MG. From the discovery cohort miR-210-3p, miR-324-3p and miR-328-3p were further analyzed in the validation cohort. We found a distinct plasma profile of miR-210-3p and miR-324-3p that were significantly decreased in MuSK+ MG patients compared to healthy controls (4.1 ± 1.4 vs 5.1 ± 1.4, p = .006 and 4.7 ± 1.0 vs 5.4 ± 1.3, p = .02). These findings reveal a distinct plasma miRNA profile in MuSK+ MG.
Introduction
Myasthenia gravis (MG) with antibodies to muscle-specific tyrosine kinase (MuSK+ MG) is a rare immunological subtype, representing 5-8% of the MG patients (Evoli et al., 2018) . Unlike MG with antibodies against AChR (AChR+MG), MuSK+MG is considered a more homogenous disease (Evoli et al., 2018) . First, it has a high prevalence of > 70% in female patients (Oh, 2009) . Secondly, the disease typically starts at early age and rarely occurs after 60 years of age (Sanders et al., 2003a) . Thirdly, the clinical features in many patients are relatively distinct with dominating cranial and bulbar muscle weakness (Evoli et al., 2018) . Lastly, association with HLA class II DQ5 alleles have been confirmed in different studies (Marino et al., 2014) . On the other hand, diagnostic challenges include less diurnal symptom fluctuations, unresponsiveness to acetylcholine esterase inhibitors and very focal findings of neuromuscular transmission failure (Evoli et al., 2018) . Biomarkers of disease activity are helpful in differentiating clinical response and outcome. MuSK antibodies are very specific but the titer does not predict the course of the disease (Kaminski et al., 2012; Meriggioli and Sanders, 2012) . As circulating microRNAs (miRNAs) play important roles in several biological processes and are easily accessible in biosamples, they are considered to fulfill the requirements for potential biomarkers also in MG (Punga and Punga, 2018) . In search of novel biomarkers for MuSK+ MG, miRNAs have been proposed as potential serum biomarkers for MuSK+ MG (Punga et al., 2016) .
Previous studies revealed a distinct elevation of 4 miRNAs: let-7a-5p, let-7f-5p, hsa-miR-151a-3p, hsa-miR-423-5p in MuSK+ MG patient sera (Punga et al., 2016) .
Circulating miRNAs in blood associate with various pathophysiological conditions. As the majority of blood samples are stored as serum, miRNA profiles of MG have so far been studied only in serum (NogalesGadea et al., 2014; Punga and Punga, 2018) . However, different expression and different types of miRNAs were found in the serum and plasma among pregnant women (Ge et al., 2015) . Due to the previously reported work that serum and plasma cannot be automatically assumed to be interchangeable with regard to miRNA concentrations (McDonald et al., 2011) , it is important to also analyze the plasma profile of MG patients. The aim of the study was therefore to analyze the circulating miRNA profile in plasma from patients with MuSK+ MG.
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